Subclinical Epstein-Barr virus viremia among adult renal transplant recipients: incidence and consequences.
Fiche publication
Date publication
mars 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHALOPIN Jean-Marc, Pr DUCLOUX Didier
Tous les auteurs :
Bamoulid J, Courivaud C, Coaquette A, Chalopin JM, Gaiffe E, Saas P, Ducloux D
Lien Pubmed
Résumé
The natural history and clinical significance of posttransplant Epstein-Barr virus (EBV) infection remain largely unknown. The aims of this study are to describe the incidence, risk factors and consequences of EBV infection after kidney transplantation. A total of 383 consecutive patients having received a kidney transplant between January 2002 and December 2010 were included. EBV polymerase chain reaction (PCR) was performed every 2 weeks for 3 months, and every 4 weeks for the next 9 months. A total of 155 of the 383 patients (40%) had at least one positive viremia during the first year posttransplant. The median time to viremia was day 31 posttransplant (14-329). A total of 73 (47%) had EBV viremia > 10(3) log and 23 (15%) had positive viremia for more than 6 months. EBV D+/R- patients (12/18 (67%) versus 143/365 (39%), p = 0.02) and those having received antithymocyte globulins (ATG) (54% vs. 35%; p
Référence
Am J Transplant. 2013 Mar;13(3):656-62